Arch Therapeutics (ARTH)
(Delayed Data from OTC)
$0.52 USD
0.00 (0.00%)
Updated Aug 28, 2024 02:42 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
Arch Therapeutics, Inc. [ARTH]
Reports for Purchase
Showing records 61 - 80 ( 115 total )
Company: Arch Therapeutics, Inc.
Industry: Medical - Instruments
Arch Adds Cash to Balance Sheet as Stock Continues Upward Sweep
Provider: IFS Securities, Inc.
Analyst: BOUCHEY D
Company: Arch Therapeutics, Inc.
Industry: Medical - Instruments
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Arch Therapeutics, Inc.
Industry: Medical - Instruments
Company: Arch Therapeutics, Inc.
Industry: Medical - Instruments
Skin Sensitization Study Progresses on Schedule; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Arch Therapeutics, Inc.
Industry: Medical - Instruments
Skin Sensitization Study Enrollment Completion and Dosing Initiation; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Arch Therapeutics, Inc.
Industry: Medical - Instruments
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Arch Therapeutics, Inc.
Industry: Medical - Instruments
Arch Has Enrolled 510(k) Study, is On-Track for FDA Filing End of Q3
Provider: IFS Securities, Inc.
Analyst: BOUCHEY D
Company: Arch Therapeutics, Inc.
Industry: Medical - Instruments
AC5 Topical Sensitization Study Enrolled, 510(k) Refiling Expected 3Q18
Provider: Roth Capital Partners, Inc.
Analyst: SOLOMON D
Company: Arch Therapeutics, Inc.
Industry: Medical - Instruments
F2Q18 Financial Results Reported; Still Expecting AC5 Regulatory Filing Next Quarter; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Arch Therapeutics, Inc.
Industry: Medical - Instruments
Management believes there are no other material items to address with the FDA
Provider: IFS Securities, Inc.
Analyst: BOUCHEY D
Company: Arch Therapeutics, Inc.
Industry: Medical - Instruments
MID-DAY SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Arch Therapeutics, Inc.
Industry: Medical - Instruments
FDA Green Lights AC5 Topical''s Sensitization Study
Provider: Roth Capital Partners, Inc.
Analyst: SOLOMON D
Company: Arch Therapeutics, Inc.
Industry: Medical - Instruments
Arch Reports Results of Quarter ending March 31 and Confirms Timeline for 510(k)
Provider: IFS Securities, Inc.
Analyst: BOUCHEY D
Company: Arch Therapeutics, Inc.
Industry: Medical - Instruments
FY2Q18 Recap - Awaiting FDA Response to AC5 Study Proposal
Provider: Roth Capital Partners, Inc.
Analyst: SOLOMON D
Company: Arch Therapeutics, Inc.
Industry: Medical - Instruments
MID-DAY SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Arch Therapeutics, Inc.
Industry: Medical - Instruments
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Arch Therapeutics, Inc.
Industry: Medical - Instruments
High-Upside Potential at a Discounted Price -Resuming Coverage
Provider: Roth Capital Partners, Inc.
Company: Arch Therapeutics, Inc.
Industry: Medical - Instruments
Further Clarity on 510(k) Resubmission; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Arch Therapeutics, Inc.
Industry: Medical - Instruments
Update on 510(k) and CE Mark filings: Better Clarity At Last and Estimated mid-2019 Launch
Provider: IFS Securities, Inc.
Analyst: BOUCHEY D
Company: Arch Therapeutics, Inc.
Industry: Medical - Instruments
What?s Happening with Arch Therapeutics? December Quarter Reported and 510(k) update.
Provider: IFS Securities, Inc.
Analyst: BOUCHEY D